

**Product Name: Recombinant Human BRD4 (N-10His-Flag)**  
**Catalog #: PEH2254**




---

## Summary

<b>Name</b>	BRD4
<b>Purity</b>	Greater than 95% as determined by reducing SDS-PAGE
<b>Endotoxin level</b>	<1 EU/μg as determined by LAL test.
<b>Construction</b>	Recombinant Human Bromodomain-containing protein 4 is produced by our E.coli expression system and the target gene encoding Glu49-Glu460 is expressed with a 10His, Flag tag at the N-terminus.
<b>Accession #</b>	O60885
<b>Host</b>	E.coli
<b>Species</b>	Human
<b>Predicted Molecular Mass</b>	49 KDa
<b>Formulation</b>	Supplied as a 0.2 μm filtered solution of 50mM HEPES, 200mM NaCl, 1mM DTT, 10% Glycerol, pH 7.5.
<b>Shipping</b>	The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
<b>Stability&amp;Storage</b>	Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
<b>Reconstitution</b>	

## SDS-PAGE image

**Product Name: Recombinant Human BRD4 (N-10His-Flag)**  
**Catalog #: PEH2254**



### **Alternative Names**

HUNK1; bromodomain-containing protein 4; HUNK1; MCAP

### **Background**

Bromodomain-containing protein 4 (BRD4) is a member of the BET class chromatin reader proteins that bind acetylated histones and play a key role in transcriptional regulation and transmission of epigenetic memory. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure. BRD bromodomains serve as recognition motifs for acetylated lysine residues on histones, while the NET domain may function by promoting phosphorylation of the C-terminal domain (CTD) of RNA Polymerase II. Some specific inhibitors of BRD4 that prevent binding to acetylated histones by binding Asn-140 and Asn-433 are promising therapeutic molecules for the treatment of leukemias. BRD4 is a potential therapeutic target in many diseases including breast cancer, AML, multiple myeloma, colon cancer and others.

### **Note**

For Research Use Only , Not for Diagnostic Use.